All of you "Strong Buy" and "Buy" fools need to get your head out of the sand or whatever orifice of your body you have it stuck up....plus, doesn't it stink up there................
.....just so they can lower the price to buy more shares of a company is delusional. These companies have reputations to maintain within the investment community and WILL NOT compromise their integrity just to buy a few cheap shares of a declining one-trick pony biotech......stop kidding yourself.
......Once the positive Interim Data is released we are sure to land a partnership with a Big Pharma who will clean house as they will not tolerate the behavior exhibited by the six thieves (seven less Schwartz) who sold-out on us in January 2014....IMHO
.....yes.......time to start spreading "the word"..........
PORTLAND, Ore., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer, will present a corporate update at two upcoming healthcare investment conferences:
Rodman & Renshaw 17th Annual Global Investment Conference
Wednesday, September 9, 2015 at 10:25 a.m. ET
St. Regis Hotel, New York, NY
NewsMakers in the Biotech Industry
Thursday, September 10, 2015 at 11:30 a.m. ET
Millennium Broadway Hotel, New York, NY
Sorry, but the file was sent directly to me via email as a PDF from HCI, so there is no link per se. It appears kwhistler64 below has posted a link; you may want to try that link.
Agreed.....see my post above to james2tx...I don't like it either, but the trial is NOT likely to be halted for efficacy.....
I posed that very question to "someone" at Galena in December 2014, and unfortunately, jslapnicka is correct, per the "official" response from Galena as follows - "The Independent Data Safety Monitoring Board will review the recurrences and give us a determination on the interim analysis when we reach 70 events. They will be looking at safety and futility and let us know if we are clear to continue the trial. They will not tell us in which arm the recurrences occurred. The primary endpoint is 141 events or 36 months and regardless of the outcomes at the interim analysis, we need to show the durability over 36 months so the trial is not expected to be stopped early for efficacy. We will announce the results of the interim analysis when it occurs which we currently predict to be late 2015/early 2016."
Jim.....I have your email from Zander and will send the presentation to you.....
Yes, with Galena and NeuVax / E75 (by name) dedicated to several slides, as were other peptide vaccines (AE-37, etc...).
Slide 85 of 89:
• Breast cancer is an immunogenic tumor
• Multiple ongoing trials are evaluating immunotherapy strategies
• Combinations are the likely way forward
Slide 86 of 89:
Is immunotherapy ready for prime time in breast cancer?
..it contains 89 slides and is 4.5M in size. I had requested a copy from the Conference Coordinator on Saturday and received it minutes ago. I will not even attempt to interpret the slides so don't even ask. The cover email also stated "Sorry I couldn’t get back earlier. Please find attached a copy of Dr. Mittendorf’s presentation. We are planning to post the entire conference as podcast in the next few days." I would check HCI's (Huntsman Cancer Institute) website periodically to see if it's been posted.
Dr. M's presentation on Sept 29th has nothing to do with Interim PH3 data................
Dan: After the latest News Release regarding the June meeting recommendation, I sent an email to Remy posing the following question - "Are these meetings on a regularly scheduled basis, and if so, when is the next one?" Her response was " The meetings are periodic throughout the trial and we don’t disclose when they occur." My guess is that because of the extreme importance of the 70th event, all kinds of red flags will go up when it occurs and will "force" an immediate meeting/review/recommendation......IMHO...............
I absolutely agree. This is not some med school intern working at a Walk-In Clinic. We are talking about "the best of the best" and she would not jeopardize her reputation or those of her peers, hospitals, research centers, etc....if she was not totally committed to NeuVax.
Possible...but not likely......IMHO. This would be "pocket change" to a Big Pharma, so I'm not sold on the "conspiracy" theory.